SlateStone Wealth LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 2,569 shares of the biopharmaceutical company’s stock, valued at approximately $237,000.
A number of other institutional investors have also made changes to their positions in GILD. HHM Wealth Advisors LLC grew its stake in shares of Gilead Sciences by 118.5% during the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 154 shares during the period. YANKCOM Partnership acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $28,000. Decker Retirement Planning Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $29,000. Crews Bank & Trust acquired a new position in Gilead Sciences in the fourth quarter valued at about $31,000. Finally, Stephens Consulting LLC grew its stake in Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 260 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
GILD has been the subject of a number of research analyst reports. Morgan Stanley boosted their target price on Gilead Sciences from $123.00 to $130.00 and gave the company an “overweight” rating in a research note on Tuesday, March 11th. JPMorgan Chase & Co. boosted their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, January 29th. Daiwa America raised Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their price objective for the stock from $80.00 to $120.00 in a research report on Tuesday, February 18th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.52.
Insider Transactions at Gilead Sciences
In related news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Over the last quarter, insiders have sold 302,785 shares of company stock worth $30,503,250. Company insiders own 0.16% of the company’s stock.
Gilead Sciences Price Performance
NASDAQ:GILD opened at $112.26 on Tuesday. The firm has a market capitalization of $139.80 billion, a price-to-earnings ratio of 303.41, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The stock’s 50 day moving average price is $102.24 and its two-hundred day moving average price is $93.16.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.
Gilead Sciences Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.81%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is 854.05%.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
- Five stocks we like better than Gilead Sciences
- What is a Stock Market Index and How Do You Use Them?
- Can TikTok Stock Picks Really Make You Rich?
- Election Stocks: How Elections Affect the Stock Market
- The “Quality” Rotation: Back to Basics Investing
- 3 Stocks to Consider Buying in October
- Occidental Petroleum: 4 Reasons to Love These Prices
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD – Free Report).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.